Navigation Links
Dysport® Clostridium Botulinum Type A

ProductsDysport® Clostridium Botulinum Type A
Company New Zealand Medical and Scientific Ltd
Item Dysport® Clostridium Botulinum Type A
Features 
Description Dysport is a simple, effective, non-surgical treatment that works by relaxing facial muscles on the forehead, thereby reducing and smoothing away frown-lines and wrinkles.

Dysport is supported by over a decade of clinical experience. Dysport was developed in the United Kingdom in the early 1990s to successfully treat a number of neurological and ophthalmic conditions. Since that time, with an increased understanding of the uses of Dysport, thousands of treatments have been safely and effectively performed for a variety of conditions ranging from frown lines to axillary hyperhidrosis (excessive sweating under the armpits).

Info New Zealand Medical and Scientific Ltd
Customer Service:
Web site: http://www.dysport.co.nz/

Related medicine products :

1. Clostridium Difficile Toxin A RAPYDTEST®
2. VIDAS Clostridium difficile (Toxin A) assay
3. Xpect Clostridium difficile Toxin A/B Test Kit
4. Clostridium botulinum Culture
5. Clostridium difficile Culture
6. Clostridium difficileCytotoxin Cell Assay
7. Clostridium difficile Toxins (A & B) by EIA
8. Culture, Clostridium difficile
9. BOTOX® Cosmetic Botulinum Toxin Type A
10. Myobloc®(Botulinum Toxin Type B) Injectable Solution
... ARIS A utomated R etinal I ... which provides rapid and automated stereo examinations of ... care professionals to screen and diagnose sight-threatening retinal ... less time and at lower cost ...
The new Riata® i lead family allows physicians even more versatility when managing patients with high defibrillation thresholds (DFTs)....
... system delivers on the promise of ... the latest advancement in fluidics control ... Lomb Surgical offers CONCENTRIX™ Fluidics Control ... provide both flow and vacuum response. ...
... thread-guide reducing time and trauma in lacrimal duct ... the nasolacrimal duct and a thin prolene thread-guide ... withdrawn leaving the polypropylene thread to pull the ... place. Newly coated with a thin Polyvinylpyrrolidone (PVP) ...
Medicine Products:
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a ... fight Fatigue . , As the stress of modern life continually makes more demands ... Constant use of artificial stimulants can trap people in vicious high/low cycles and can ...
(Date:8/22/2017)... ... 22, 2017 , ... Although Labor Day is not as popular for fireworks ... weekend displays, and numerous households celebrate the unofficial end of summer with backyard fireworks ... pets. , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... risk to health and safety. By learning and implementing best practices for containment ... In this webinar, attendees will gain a better understanding of a method for ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... the addition of two plastic surgery fellows for academic year 2017-2018, Christina M. ... candidates who have successfully completed residency in Plastic and Reconstructive Surgery. The ...
(Date:8/21/2017)... ... August 21, 2017 , ... SportsEngine, Inc. , ... Official Technology Partner of North Country Region Volleyball and will power registration, scheduling, ... along with providing sport management software to their member clubs. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: